Stem Cell Transplantation

Subscribe to Selected New Research on Stem Cell Transplantation

4626 relevant articles (468 outcomes, 446 trials/studies) found for this Therapy

Description: The transfer of STEM CELLS from one individual to another within the same species (TRANSPLANTATION, HOMOLOGOUS) or between species (XENOTRANSPLANTATION), or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). The source and location of the stem cells determines their potency or pluripotency to differentiate into various cell types.

Also Known As:

Stem Cell Transplantations; Transplantations, Stem Cell; Transplantation, Stem Cell

Relationship Network

Therapy Context: Research Results

Operative Surgical Procedures: 4

Transplantation: 36653

Cell Transplantation: 1175

Stem Cell Transplantation: 4626

Hematopoietic Stem Cell Transplantation: 2408

Peripheral Blood Stem Cell Transplantation: 1228

Cord Blood Stem Cell Transplantation: 53

Mesenchymal Stem Cell Transplantation: 27

Experts

1.	Nagler, Arnon: 20 articles (09/2008 - 01/2002)
2.	Sureda, A: 19 articles (04/2008 - 01/2000)
3.	Kröger, Nicolaus: 18 articles (09/2008 - 12/2002)
4.	Gertz, Morie A: 17 articles (09/2008 - 06/2002)
5.	Champlin, Richard E: 17 articles (09/2008 - 01/2002)
6.	Lacy, Martha Q: 16 articles (10/2008 - 11/2002)
7.	Dispenzieri, Angela: 16 articles (09/2008 - 11/2002)
8.	Carreras, Enric: 16 articles (08/2008 - 04/2002)
9.	Niederwieser, D: 16 articles (04/2007 - 09/2000)
10.	Kröger, N: 16 articles (04/2007 - 01/2000)

Related Diseases

1.	Multiple Myeloma 11/15/2008 - "Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation." 12/01/2007 - "Whether these early results will lead to prolonged overall survival and thereby ultimately redefine the role of stem cell transplantation in first-line treatment of multiple myeloma will be one of the most important questions to be answered in the coming years" 04/01/2008 - "OBJECTIVE: To evaluate the efficacy of autologous stem cell transplantation (ASCT) in the treatment of multiple myeloma (MM) and its impact on the prognosis of MM. METHODS: Retrospective analysis was performed in 28 patients with MM (group A) treated with ASCT in our hospital from October 1998 to February 2007, compared with those not received ASCT in the same time period including 23 patients with near complete response (nCR) or better (group B) and 25 patients with partial response (PR) (group C)" 11/01/2006 - "Induction regimens prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma patients usually result in complete remission (CR) rates of <10%" 01/01/2004 - "High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission." Order ALL the reference details at left...
2.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 08/01/2006 - "Most studies showing that autologous stem cell transplantation (ASCT) is feasible in older patients with acute myeloid leukemia (AML) referred to highly selected patients considered as eligible after complete remission (CR) achievement and bone marrow or peripheral blood stem cell (PBSC) collection" 04/01/2008 - "Our period analysis reveals major improvement on the population level in long-term prognosis of younger patients with acute myeloblastic leukemia, most likely explained by multiple incremental improvements in care including better and more specific diagnosis, improvements in and extension of the use of stem cell transplantation and high dose therapy, and improved supportive care." 07/01/2005 - "Autologous or allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapy." 03/01/2007 - "Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study." 08/15/2003 - "Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial." Order ALL the reference details at left...
3.	Non-Hodgkin Lymphoma (Lymphosarcoma) 10/01/2002 - "Autologous stem cell transplantation as upfront first line therapy for patients with aggressive non-Hodgkin s lymphoma does not contribute to a better outcome, most certainly not if it concerns patients with a favorable risk profile" 02/01/1998 - "The aim of the study was to retrospectively evaluate the outcome of patients with aggressive non-Hodgkin's lymphoma (NHL), undergoing autologous stem cell transplantation (ASCT) in first complete (CR) or partial (PR) remission, according to the age-adjusted International Prognostic Index (IPI)" 02/01/2003 - "High-dose chemotherapy and autologous stem cell transplantation (ASCT) is a potentially curative therapy for younger patients with relapsed aggressive non-Hodgkin's lymphoma, and is under investigation as first-line treatment and as therapy for indolent and mantle cell non-Hodgkin's lymphoma" 02/01/2002 - "The combination of high-dose chemotherapy and autologous stem cell transplantation (ASCT) is a potentially curative therapy for patients with relapsed chemosensitive non-Hodgkin's lymphoma (NHL) and is increasingly being considered as a first-line treatment for NHL patients with poor prognosis or poor outcomes from chemotherapy" 06/01/2007 - "BACKGROUND: Randomized controlled trials (RCTs) reported conflicting results on the impact of high-dose chemotherapy (HDCT) and autologous stem cell transplantation in the first-line treatment of patients with aggressive non-Hodgkin lymphoma (NHL)" Order ALL the reference details at left...
4.	Leukemia 11/01/2007 - "The results of allogeneic stem cell transplantation for patients with chemotherapy-resistant non-remission acute leukemia have been very poor" 05/01/2007 - "INTERPRETATION AND CONCLUSIONS: The kinetics of MRD clearance may help to identify patients at high risk of leukemia relapse after allogeneic stem cell transplantation" 03/01/2002 - "Recent clinical observations suggest that effective treatment of leukemia may be accomplished with a well-tolerated nonmyeloablative stem cell transplantation (NST) regimen, while avoiding immediate and late toxicity and minimizing procedure-related mortality" 07/01/2007 - "This study aims to assess the cost-effectiveness of stem cell transplantation from either cord blood or bone marrow/peripheral blood compared with no transplantation in adult patients with acute leukemias not expected to be cured with chemotherapy" 03/01/2008 - "Allogeneic stem cell transplantation (SCT) offers the only hope for cure for many adults with acute leukemia" Order ALL the reference details at left...
5.	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 10/01/1998 - "BACKGROUND AND OBJECTIVE: The best post-remission therapy for patients with acute lymphoblastic leukemia (ALL) is controversial, and hemopoietic stem cell transplantation (HSCT) is one therapeutic option" 06/01/2008 - "Allogeneic hemopoietic stem cell transplantation for childhood acute lymphoblastic leukemia in second complete remission-similar outcomes after matched related and unrelated donor transplant: a study of the Spanish Working Party for Blood and Marrow Transplantation in Children (Getmon)." 02/01/2006 - "To evaluate the results of autologous stem cell transplantation (ASCT) in a large population of adults with acute lymphoblastic leukemia (ALL) in first complete remission (CR), we performed an individual data-based overview of the last three trials from the LALA group" 02/01/2006 - "Autologous stem cell transplantation in adults with acute lymphoblastic leukemia in first complete remission: analysis of the LALA-85, -87 and -94 trials." 09/01/2004 - "We performed HLA-mismatched stem cell transplantations with megadoses of purified positively selected mobilized peripheral blood CD34+ progenitor cells (PBPC) from adult donors in 27 children with acute lymphoblastic leukemia (ALL) in first (CR1 n = 7), second (CR2 n = 10), or third (CR3 n = 4) complete remission, and in refractory state (NR n = 6)" Order ALL the reference details at left...

Related Drugs and Biologics

1.	Melphalan (Alkeran)
2.	Cyclophosphamide (Cytoxan)
3.	rituximab (Mabthera)
4.	imatinib (Gleevec)
5.	Etoposide (VP 16)
6.	Cytarabine (Cytosar-U)
7.	Thalidomide (Thalomid)
8.	fludarabine
9.	Antigens
10.	Granulocyte Colony-Stimulating Factor (G-CSF)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Transplants (Transplant)
3.	Transplantation (Transplant Recipients)
4.	Immunotherapy
5.	Homologous Transplantation (Allograft)

Best Treatments:
Research Summary Report
on Multiple Myeloma

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 597 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>